Avian influenza pandemic preparedness: Developing prepandemic and pandemic vaccines against a moving target

Expert Reviews in Molecular Medicine

Volumn 12, Issue , 2010, Pages

  Singh, Neetu ^a   Pandey, Aseem ^a   Mittal, Suresh K ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMANTADINE; DNA VACCINE; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; OSELTAMIVIR; ZANAMIVIR; VIRUS PROTEIN;

ANTIBODY TITER; AVIAN INFLUENZA; BACTERIAL STRAIN; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RESISTANCE; INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PUBLIC HEALTH SERVICE; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; STRATEGIC PLANNING; TREATMENT RESPONSE; VACCINE PRODUCTION; VIRUS PARTICLE; ANIMAL; BIRD; EPIDEMIC; IMMUNOLOGY; INFLUENZA; METHODOLOGY; VACCINATION;

ANIMALS; BIRDS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION; VIRAL PROTEINS;

EID: 77955505570     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399410001432     Document Type: Review

References (210)

1. Johnson, N.P. and Mueller, J. (2002) Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bulletin of the History of Medicine 76, 105-115
2. de Jong, J.C. et al. (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of Medical Virology 61, 94-99
3. Kawaoka, Y., Krauss, S. and Webster, R.G. (1989) Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. Journal of Virology 63, 4603-4608 (Pubitemid 19257834)
4. Scholtissek, C. et al. (1978) On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology 87, 13-20 (Pubitemid 8359271)
5. Webster, R.G. et al. (1992) Evolution and ecology of influenza A viruses. Microbiological Reviews 56, 152-179
6. Taubenberger, J.K. et al. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437, 889-893 (Pubitemid 41486764)
7. Smith, G.J. et al. (2009) Dating the emergence of pandemic influenza viruses. Proceedings of the National Academy of Sciences of the United States of America 106, 11709-11712
8. Dawood, F.S. et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New England Journal of Medicine 360, 2605-2615
9. Bender, C. et al. (1999) Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology 254, 115-123 (Pubitemid 29391719)
10. Centers for Disease Control (1997) Isolation of avain influenza A (H5N1) viruses from humans - Hong Kong May-December 1997. Morbidity and Mortality Weekly Report 46, 1204-1207
11. Katz, J.M. et al. (1999) Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. Journal of Infectious Diseases 180, 1763-1770
12. Matrosovich, M. et al. (1999) The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. Journal of Virology 73, 1146-1155 (Pubitemid 29036766)
13. Shortridge, K.F. et al. (1998) Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 252, 331-342 (Pubitemid 29013415)
14. Yuen, K.Y. et al. (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351, 467-471 (Pubitemid 28070092)
15. Subbarao, K. et al. (1998) Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279, 393-396 (Pubitemid 28063376)
16. Centers for Disease Control (2003) Update: Influenza activity - United States and Worldwide, 2002-2003 season and composition of the 2003-2004 influenza vaccine. Morbidity and Mortality Weekly Report 52, 516-521
17. WHO (2009) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian-influenza/ country/cases-table-2009-09-24/en/index.html.
18. Liu, D. et al. (2009) Interspecies transmission and host restriction of avian H5N1 influenza virus. Science in China Series C Life Sciences 52, 428-438
19. Guo, Y.J. et al. (2000) Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. Virology 267, 279-288 (Pubitemid 30123610)
20. Peiris, M. et al. (1999) Human infection with influenza H9N2. Lancet 354, 916-917 (Pubitemid 29424025)
21. Lin, Y.P. et al. (2000) Avian-to-human transmission of H9N2 subtype influenza Aviruses: relationship between H9N2 and H5N1 human isolates. Proceedings of the National Academy of Sciences of the United States of America 97, 9654-9658 (Pubitemid 30650831)
22. Fouchier, R.A. et al. (2004) Avian influenza Avirus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proceedings of the National Academy of Sciences of the United States of America 101, 1356-1361 (Pubitemid 38182693)
23. Webby, R.J. and Webster, R.G. (2003) Are we ready for pandemic influenza? Science 302, 1519-1522 (Pubitemid 37475685)
24. FLU.gov (2009) CDC: 38 million doses of H1N1 vaccine available. http://www.flu.gov/news/blogs/vaccine38million.html
25. Fox, M. (2010) U.S. slashes swine flu vaccine estimate. http://abcnews.go.com/Health/SwineFluNews/story?id=8346897
26. Donnelly, J.J. et al. (1995) Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nature Medicine 1, 583-587
27. Cox, N.J. and Subbarao, K. (2000) Global epidemiology of influenza: past and present. Annual Review of Medicine 51, 407-421 (Pubitemid 30216046)
28. Chen, H. et al. (2006) Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proceedings of the National Academy of Sciences of the United States of America 103, 2845-2850
29. U.S.FDA(2009) Influenza (Flu) antiviral drugs and related information. http://www.fda.gov/cder/drug/antivirals/influenza/
30. Cheung, C.L. et al. (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. Journal of Infectious Diseases 193, 1626-1629
31. de, J. et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. New England Journal of Medicine 353, 2667-2672
32. Moscona, A. (2005) Oseltamivir resistance-disabling our influenza defenses. New England Journal of Medicine 353, 2633-2636
33. Dharan, N.J. et al. (2009) Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. Journal of the American Medical Association 301, 1034-1041
34. Gooskens, J. et al. (2009) Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. Journal of the American Medical Association 301, 1042-1046
35. Weinstock, D.M. and Zuccotti, G. (2009) The evolution of influenza resistance and treatment. Journal of the American Medical Association 301, 1066-1069
36. Le, M.T. et al. (2008) Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS ONE 3, e3339
37. Kimm-Breschkin, J.L. et al. (2007) Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerging Infectious Diseases 13, 1354-1357 (Pubitemid 47510297)
38. WHO (2009) Oseltamivir resistance in immunocompromised hospital patients. http://www.who.int/csr/disease/swineflu/notes/briefing-20091202/en/index.html
39. Patel, A. and Gorman, S.E. (2009) Stockpiling antiviral drugs for the next influenza pandemic. Clinical Pharmacology and Therapeutics 86, 241-243
40. De, C.E. (2006) Antiviral agents active against influenza A viruses. Nature Reviews Drug Discovery 5, 1015-1025
41. Hayden, F. (2009) Developing newantiviral agents for influenza treatment: what does the future hold? Clinical Infectious Diseases 48 (Suppl 1), S3-13
42. Lau, Y.F., Tang, L.H. and Ooi, E.E. (2009) A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27, 1354-1364
43. Wong, J.P. et al. (2009) Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Current Pharmaceutical Design 15, 1269-1274
44. Bell, D.M. (2006) Non-pharmaceutical interventions for pandemic influenza, national and community measures. Emerging Infectious Diseases 12, 88-94
45. Hoelscher, M. et al. (2008) Vaccines against epidemic and pandemic influenza. Expert Opinion on Drug Delivery 5, 1139-1157
46. Ilyinskii, P.O., Thoidis, G. and Shneider, A.M. (2008) Development of a vaccine against pandemic influenza viruses: current status and perspectives. International Reviews of Immunology 27, 392-426
47. Gerdil, C. (2003) The annual production cycle for influenza vaccine. Vaccine 21, 1776-1779
48. Tree, J.A. et al. (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 19, 3444-3450 (Pubitemid 32710294)
49. Roos, R. (2009) Pandemic vaccine?making capacity rising, but still short. http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/feb2409vaccine- jw.html.
50. U.S. FDA (2003) Approval letter - influenza virus vaccine live, intranasal. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ ucm123753.htm
51. Tosh, P.K., Boyce, T.G. and Poland, G.A. (2008) Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clinic Proceedings 83, 77-84
52. Gorse, G.J., Belshe, R.B. and Munn, N.J. (1988) Local and systemic antibody responses in high-risk adults given live-attenuated and inactivated influenza A virus vaccines. Journal of Clinical Microbiology 26, 911-918
53. Gorse, G.J., Belshe, R.B. and Munn, N.J. (1991) Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 100, 977-984
54. Treanor, J.J. et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18, 899-906
55. Belshe, R.B. et al. (2007) Live attenuated versus inactivated influenza vaccine in infants and young children. New England Journal of Medicine 356, 685-696
56. Ashkenazi, S. et al. (2006) Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatric Infectious Disease Journal 25, 870-879 (Pubitemid 44510578)
57. Fleming, D.M. et al. (2006) Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatric Infectious Disease Journal 25, 860-869 (Pubitemid 44510577)
58. Belshe, R.B. et al. (2000) Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. Journal of Pediatrics 136, 168-175 (Pubitemid 30470986)
59. PATH (Program for Appropriate Technology in Health) and Oliver Wyman (2009) Influenza vaccine strategies for broad global access. http://www.oliverwyman.com/ow/pdf-files/VAC-infl-publ-rpt-10-07.pdf
60. Gabriel, G. et al. (2008) The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 26, 956-965
61. Govorkova, E.A. et al. (2005) Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. Journal of Virology 79, 2191-2198 (Pubitemid 40204576)
62. Nicolson, C. et al. (2005) Generation of influenza vaccine viruses onVero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23, 2943-2952 (Pubitemid 40386496)
63. Horimoto, T. and Kawaoka, Y. (1994) Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. Journal of Virology 68, 3120-3128 (Pubitemid 24129761)
64. Senne, D.A. et al. (1996) Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Diseases 40, 425-437 (Pubitemid 26310993)
65. Steel, J. et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. Journal of Virology 83, 1742-1753
66. Suguitan, A.L., Jr et al. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Medicine 3, e360
67. Joseph, T. et al. (2008) A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378, 123-132
68. WHO (2009) Tables on the clinical trials of pandemic influenza prototype vaccines. http://www.who.int/vaccine-research/diseases/influenza/flu-trials- tables/en/
69. Desheva, J.A. et al. (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24, 6859-6866 (Pubitemid 46107188)
70. The European Agency for the Evaluation of Medicinal Products (2004) European Committee for Proprietary Medicinal Products. Guideline on submission of marketing authorisation applications for pandemic influenza vaccines through the centralised procedure. http://www.emea.europa.eu/pdfs/human/vwp/498603en.pdf
71. U.S. FDA (2007) Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. http://www.fda.gov/cber/gdlns/ panfluvac.htm
72. Eichelberger, M. et al. (2008) FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26, 4299-4303
73. Lin, J. et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368, 991-997 (Pubitemid 44353667)
74. Brady, M.I. and Furminger, I.G. (1976) A surface antigen influenza vaccine. 2. Pyrogenicity and antigenicity. Journal of Hygiene 77, 173-180
75. Davenport, F.M. et al. (1964) Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. Journal of Laboratory and Clinical Medicine 63, 5-13
76. Laver, W.G. and Webster, R.G. (1976) Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. Virology 69, 511-522
77. Stephenson, I. et al. (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362, 1959-1966 (Pubitemid 37548419)
78. Wu, J. et al. (2009) Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial. Clinical Infectious Diseases 48, 1087-1095
79. Fazekas, G. et al. (2009) Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clinical and Vaccine Immunology 16, 437-443
80. Vajo, Z. et al. (2008) Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatric Infectious Disease Journal 27, 1052-1056
81. Mutsch, M. et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England Journal of Medicine 350, 896-903 (Pubitemid 38252537)
82. Treanor, J.J. et al. (2006) Safetyand immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England Journal of Medicine 354, 1343-1351
83. U.S. FDA (2007) approves first U.S. vaccine for humans against the avian influenza virus H5N1. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2007/ucm108892.htm
84. Zangwill, K.M. et al. (2008) Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. Journal of Infectious Diseases 197, 580-583 (Pubitemid 351321536)
85. Leroux-Roels, I. et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580-589 (Pubitemid 47247854)
86. Levie, K. et al. (2008) An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Journal of Infectious Diseases 198, 642-649
87. Nicholson, K.G. et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943 (Pubitemid 32568336)
88. Bernstein, D.I. et al. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Journal of Infectious Diseases 197, 667-675 (Pubitemid 351364465)
89. Leroux-Roels, I. et al. (2008) Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE 3, e1665
90. Bresson, J.L. et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367, 1657-1664
91. Keitel, W.A. et al. (2008) Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. Journal of Infectious Diseases 198, 1309-1316
92. Nolan, T.M. et al. (2008) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26, 4160-4167
93. Stephenson, I. et al. (2003) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21, 1687-1693 (Pubitemid 36287599)
94. Stephenson, I. et al. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. Journal of Infectious Diseases 191, 1210-1215
95. Baras, B. et al. (2008) Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3, e1401
96. Rumke, H.C. et al. (2008) Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26, 2378-2388
97. Banzhoff, A. et al. (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE 4, e4384
98. Chotpitayasunondh, T. et al. (2008) Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split-virion influenza A/H5N1 vaccine in children. PLoS ONE 3, e4028
99. Nolan, T. et al. (2008) Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26, 6383-6391
100. Jennings, L.C. et al. (2008) Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infectious Diseases 8, 650-658
101. Stephenson, I. et al. (2008) Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. New England Journal of Medicine 359, 1631-1633
102. Galli, G. et al. (2009) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proceedings of the National Academy of Sciences of the United States of America 106, 7962-7967
103. U.S. Department of Health & Human Sciences (2009) HHS awards $487 million contract to build first U.S. manufacturing facility for cell-based influenza vaccine. http://www.hhs.gov/news/press/2009pres/01/ 20090115b.html
104. Roos, R. (2006) US awards $1 billion for cell-based flu vaccines. http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/may0406vaccines. html.
105. Novartis (2007) Novartis gains European approval for its innovative flu vaccine Optaflu®. http://hugin.info/134323/R/1132639/211845.pdf
106. Initiative for Vaccine Research, WHO (2007) Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing, and regulatory considerations. http://www.who.int/vaccine- research/diseases/influenza/WHO-Flu-Cell-Substrate-Version3.pdf
107. Hardy, C.T. et al. (1995) Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211, 302-306
108. Robertson, J.S. et al. (1985) Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143, 166-174 (Pubitemid 15113230)
109. Schild, G.C. et al. (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303, 706-709 (Pubitemid 13106735)
110. Gregersen, J.P. (2008) A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 26, 3332-3340
111. Howard, M.K., Kistner, O. and Barrett, P.N. (2008) Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biological Chemistry 389, 569-577 (Pubitemid 351874194)
112. Kistner, O. et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25, 6028-6036 (Pubitemid 47077543)
113. Palker, T. et al. (2004) Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants. Virus Research 105, 183-194 (Pubitemid 39213936)
114. Ehrlich, H.J. et al. (2008) A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. New England Journal of Medicine 358, 2573-2584 (Pubitemid 351831358)
115. U.S. National Institutes of Health (2007) Phase 3 immunogenicity and safety study of an inactivated H5N1 influenza vaccine (whole virion, vero cell derived). http://clinicaltrial.gov/ct2/show/NCT00462215?term= avian+influenza&rank=16
116. U.S. National Institutes of Health (2008) Phase III study of a H5N1 vaccine in adults, elderly and specified risk groups. http://clinicaltrial.gov/ ct2/show/NCT00711295?term=avian+influenza&rank=34
117. Ikonomou, L., Schneider, Y.J. and Agathos, S.N. (2003) Insect cell culture for industrial production of recombinant proteins. Applied Microbiology and Biotechnology 62, 1-20 (Pubitemid 36836534)
118. Altmann, F. et al. (1999) Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconjugate Journal 16, 109-123 (Pubitemid 29472137)
119. Safdar, A. and Cox, M.M. (2007) Baculovirus-expressed influenza vaccine. A novel technology for safe and expeditious vaccine production for human use. Expert Opinion on Investigational Drugs 16, 927-934 (Pubitemid 47074153)
120. Huber, V.C. and McCullers, J.A. (2008) FluBlok, a recombinant influenza vaccine. Current Opinion in Molecular Therapeutics 10, 75-85 (Pubitemid 351170598)
121. Roos, R. (2007) Insect-cell-based flu vaccine looks good in clinical trial. http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/ apr1207cell.html
122. Lakey, D.L. et al. (1996) Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. Journal of Infectious Diseases 174, 838-841 (Pubitemid 26325903)
123. Powers, D.C. et al. (1997) Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. Journal of Infectious Diseases 175, 342-351 (Pubitemid 27052240)
124. Treanor, J.J. et al. (1996) Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. Journal of Infectious Diseases 173, 1467-1470 (Pubitemid 26286808)
125. Treanor, J.J. et al. (2001) Safetyand immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19, 1732-1737 (Pubitemid 32175735)
126. Goji, N.A. et al. (2008) Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Journal of Infectious Diseases 198, 635-641
127. Grgacic, E.V. and Anderson, D.A. (2006) Virus-like particles: passport to immune recognition. Methods 40, 60-65 (Pubitemid 44415499)
128. Ludwig, C. and Wagner, R. (2007) Virus-like particles-universal molecular toolboxes. Current Opinion in Biotechnology 18, 537-545
129. Roy, P. and Noad, R. (2008) Virus-like particles as a vaccine delivery system: myths and facts. Human Vaccines 4, 5-12 (Pubitemid 351785255)
130. U.S. FDA (2006) FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. http://www.fda.gov/bbs/topics/news/2006/new01385.html
131. U.S. FDA (2009) Gardasil. http://www.fda.gov/cber/products/gardasil.htm
132. Bright, R.A. et al. (2008) Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3, e1501
133. Kang, S.M. et al. (2009) Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS ONE 4, e4667
134. Mahmood, K. et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26, 5393-5399
135. Perrone, L.A. et al. (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. Journal of Virology 83, 5726-5734
136. Hayden, F.G. et al. (2009) Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine 27, 4079-4089
137. Quan, F.S. et al. (2008) A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26, 3352-3361
138. Feltquate, D.M. et al. (1997) Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. Journal of Immunology 158, 2278-2284 (Pubitemid 127470012)
139. Huber, V.C. et al. (2006) Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clinical and Vaccine Immunology 13, 981-990 (Pubitemid 44518965)
140. Ulmer, J.B. et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745-1749 (Pubitemid 23114660)
141. Webster, R.G. and Robinson, H.L. (1997) DNA vaccines: a review of developments. BioDrugs 8, 273-292 (Pubitemid 27440675)
142. Luxembourg, A., Evans, C.F. and Hannaman, D. (2007) Electroporation-based DNA immunisation: translation to the clinic. Expert Opinion on Biological Therapy 7, 1647-1664 (Pubitemid 350161649)
143. Sharpe, M. et al. (2007) Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25, 6392-6398 (Pubitemid 47090232)
144. Wang, S. et al. (2008) The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 26, 2100-2110
145. Ulmer, J.B., Wahren, B. and Liu, M.A. (2006) Gene-based vaccines: recent technical and clinical advances. Trends in Molecular Medicine 12, 216-222 (Pubitemid 43728411)
146. Huber, V.C., Thomas, P.G. and McCullers, J.A. (2009) A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 27, 1192-1200
147. Chen, M.W. et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proceedings of the National Academy of Sciences of the United States of America 105, 13538-13543
148. Epstein, S.L. et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging Infectious Diseases 8, 796-801
149. Epstein, S.L. et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23, 5404-5410 (Pubitemid 41579312)
150. Laddy, D.J. et al. (2008) Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE 3, e2517
151. Laddy, D.J. et al. (2009) Electroporation of synthetic DNA antigens offers protection in non-human primates challenged with highly pathogenic avian influenza. Journal of Virology 83, 4624-4630
152. Hartikka, J. et al. (2001) Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19, 1911-1923 (Pubitemid 32178339)
153. Reyes, L. et al. (2001) Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19, 3778-3786 (Pubitemid 32522777)
154. Medical News Today (2008) Vical announces breakthrough for pandemic influenza DNA vaccines with preliminary human data. http://www.medicalnewstoday. com/articles/115420.php
155. Medical News Today (2006) NIAID DNA vaccine for H5N1 avian influenza enters human trial. http://www.medicalnewstoday.com/articles/60091.php
156. Bangari, D.S. and Mittal, S.K. (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24, 849-862 (Pubitemid 43185300)
157. Zhu, J., Huang, X. and Yang, Y. (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. Journal of Virology 81, 3170-3180 (Pubitemid 46456626)
158. Fooks, A.R. et al. (1995) High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in amurine model.Virology 210, 456-465
159. Gao, W. et al. (2003) Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362, 1895-1896 (Pubitemid 37518507)
160. Gomez-Roman, V.R. (2003) HIV/AIDS prevention programs in developing countries are deficient without an appropriate scientific research infrastructure. AIDS 17, 1114-1116
161. Lubeck, M.D. et al. (1989) Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proceedings of the National Academy of Sciences of the United States of America 86, 6763-6767 (Pubitemid 19236341)
162. Sullivan, N.J. et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681-684 (Pubitemid 36987993)
163. Gao, W. et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. Journal of Virology 80, 1959-1964 (Pubitemid 43228735)
164. Hoelscher, M.A. et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475-481 (Pubitemid 43208903)
165. Holman, D.H. et al. (2008) Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 26, 2627-2639
166. Hoelscher, M.A. et al. (2007) New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clinical Pharmacology and Therapeutics 82, 665-671 (Pubitemid 350114832)
167. Hoelscher, M.A. et al. (2008) A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. Journal of Infectious Diseases 197, 1185-1188 (Pubitemid 351590054)
168. Van Kampen, K.R. et al. (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23, 1029-1036 (Pubitemid 40037652)
169. Kostense, S. et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213-1216 (Pubitemid 38738525)
170. Catanzaro, A.T. et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. Journal of Infectious Diseases 194, 1638-1649 (Pubitemid 44901994)
171. Barouch, D.H. et al. (2003) Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. Journal of Virology 77, 8729-8735 (Pubitemid 36936084)
172. Roy, S. et al. (2007) Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine 25, 6845-6851 (Pubitemid 47398928)
173. Singh, N. et al. (2008) Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Molecular Therapy 16, 965-971 (Pubitemid 351587108)
174. Yang, Z.Y. et al. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. Journal of Virology 77, 799-803
175. Lundstrom, K. (2003) Alphavirus vectors for vaccine production and gene therapy. Expert Review of Vaccines 2, 447-459
176. Pushko, P. et al. (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. Journal of Virology 75, 11677-11685 (Pubitemid 33063259)
177. Schultz-Cherry, S. et al. (2000) Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278, 55-59 (Pubitemid 32002594)
178. Velders, M.P. et al. (2001) Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Research 61, 7861-7867 (Pubitemid 33049376)
179. Hubby, B. et al. (2007) Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 25, 8180-8189 (Pubitemid 350046318)
180. Aphavax (2007) Alphavax announces results from phase I influenza vaccine clinical trial. http://www.alphavax.com/docs/pr/release-43.pdf.
181. Ge, J. et al. (2007) Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. Journal of Virology 81, 150-158 (Pubitemid 44975155)
182. Veits, J. et al. (2006) Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proceedings of the National Academyof Sciences of the United States of America 103, 8197-8202 (Pubitemid 43801075)
183. Huang, Z. et al. (2003) Recombinant Newcastle disease virus as a vaccine vector. Poultry Science 82, 899-906 (Pubitemid 38641901)
184. Bukreyev, A. and Collins, P.L. (2008) Newcastle disease virus as a vaccine vector for humans. Current Opinion in Molecular Therapeutics 10, 46-55 (Pubitemid 351170594)
185. DiNapoli, J.M. et al. (2007) Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. Journal of Virology 81, 11560-11568 (Pubitemid 47623787)
186. Geisbert, T.W. et al. (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathogens 4, e1000225
187. Geisbert, T.W. et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26, 6894-6900
188. Iyer, A.V. et al. (2009) Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine 27, 893-903
189. Kapadia, S.U., Simon, I.D. and Rose, J.K. (2008) SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology 376, 165-172
190. Roberts, A. et al. (1998) Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. Journal of Virology 72, 4704-4711 (Pubitemid 28215645)
191. Roediger, E.K. et al. (2008) Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Molecular Therapy 16, 1161-1169 (Pubitemid 351737083)
192. Zinkernagel, R.M., Adler, B. and Holland, J.J. (1978) Cell-mediated immunity to vesicular stomatitis virus infections in mice. Experimental Cell Biology 46, 53-70 (Pubitemid 8216379)
193. Schwartz, J.A. et al. (2007) Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366, 166-173 (Pubitemid 47314403)
194. Kalhoro, N.H. et al. (2009)Arecombinant vesicular stomatitis virus replicon vaccine protects chickens from highly pathogenic avian influenza virus (H7N1). Vaccine 27, 1174-1183
195. Smith, G.L. and Moss, B. (1983) Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25, 21-28 (Pubitemid 14241202)
196. Lockey, T.D. et al. (2008) Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Frontiers in Bioscience 13, 5916-5927
197. Altstein, A.D. et al. (2006) Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Archives of Virology 151, 921-931
198. Jakeman, K.J., Smith, H. and Sweet, C. (1989) Mechanism of immunity to influenza: maternal and passive neonatal protection following immunization of adult ferrets with a live vaccinia-influenza virus haemagglutinin recombinant but not with recombinants containing other influenza virus proteins. Journal of General Virology 70, 1523-1531 (Pubitemid 19165613)
199. Sutter, G. et al. (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032-1040 (Pubitemid 24246876)
200. Poon, L.L. et al. (2009) Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. Journal of Immunology 182, 3063-3071
201. Mayrhofer, J. et al. (2009) Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. Journal of Virology 83, 5192-5203
202. Luke, T.C. et al. (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of Internal Medicine 145, 599-609 (Pubitemid 46780940)
203. Simmons, C.P. et al. (2007) Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Medicine 4, e178
204. Kashyap, A.K. et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proceedings of the National Academyof Sciences of the United States of America 105, 5986-5991 (Pubitemid 351758386)
205. Throsby, M. et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942
206. Wrammert, J. et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (Pubitemid 351769295)
207. Ekiert, D.C. et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246-251
208. Sui, J. et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza Aviruses. Nature Structural and Molecular Biology 16, 265-273
209. Khurana, S. et al. (2009) Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Medicine 6, e1000049
210. Khurana, S. et al. (2006) Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. Journal of Virology 80, 2092-2099 (Pubitemid 43271516)